No CrossRef data available.
Article contents
Amisulpride-induced neuroleptic malignant syndrome
Published online by Cambridge University Press: 24 June 2014
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0924270800001812/resource/name/firstPage-S0924270800001812a.jpg)
- Type
- Comment & Critique
- Information
- Copyright
- Copyright © 2008 Blackwell Munksgaard
References
Herrera-Estrella, M,
Apiquian, R,
Fresan, A,
Sanchez-Torres, I.
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
BMC Psychiatry 2005:5:22.
CrossRefGoogle ScholarPubMed
Atbasoglu, EC,
Ozguven, HD,
Can Saka, M,
Goker, C.
Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome.
J Clin Psychiatry 2004;65:1724–1725.
CrossRefGoogle ScholarPubMed
Bottlender, R,
Jager, M,
Hofschuster, E,
Dobmeier, P,
Moller, HJ.
Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient.
Pharmacopsychiatry 2002;35:119–121.
CrossRefGoogle ScholarPubMed
American Psychiatry Association.
Diagnostic and statistical manual for mental disorders, 4th edn. Washington DC: American Psychiatry Association, 1994.
Google ScholarPubMed
Sachdev, P,
Mason, C,
Hadzi-Pavlovic, D.
Case-control study of neuroleptic malignant syndrome.
Am J Psychiatry 1997;154:1156–1158.
Google ScholarPubMed